EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders

Anja Torsvik iD, Andrea Trentani, Tomasz K Stokowy, Silje Skrede, Inge Joa, Solveig M Klæbo Reitan, Maria Rettenbacher, Rune A Kroken, Erik Johnsen, Vidar M Steen

International Journal of Neuropsychopharmacology · 02.06.2026 · 29 (6)

DOI: 10.1093/ijnp/pyag019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 25.04.2026. Verfasst von Anja Torsvik und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Aripiprazole, Antipsychotic Agents, Olanzapine, Amisulpride. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Trond Mohn Research Foundation, Dr. Einar Martens Foundation, Western Norway Regional Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Antipsychotic drugs are to varying degrees associated with hematological side-effects and peripheral metabolic and immunological changes. Here, we aimed to characterize the initial transcriptional changes in peripheral leukocytes from individuals with schizophrenia spectrum disorder (SSD) after starting antipsychotic treatment with amisulpride, aripiprazole, or olanzapine.

Methods

We analyzed RNA sequencing data obtained from peripheral whole blood samples from 100 individuals with SSD (41 antipsychotic-naïve [AP-naïve], 10 AP-free, and 49 AP-switching at inclusion) collected at baseline and after 1 and 3 weeks of antipsychotic drug use. Data from 36 healthy controls (HC) collected at baseline and after 3 weeks without any intervention were included. We analyzed age- and sex-adjusted differentially expressed genes between SSD and HC before and after treatment and stratified by previous antipsychotic use. A linear mixed model was applied to study longitudinal gene expression changes associated with the antipsychotic drug that was used.

Results

After 3 weeks of antipsychotic use, the AP-switching group had the most significant transcriptional changes, characterized by increased expression of genes typically transcribed by immature erythroid cells and immature neutrophil cells. This gene profile showed no correlation with symptoms score. Interestingly, the immature neutrophil-associated gene signature was more pronounced in participants receiving olanzapine, and partly also amisulpride, but not aripiprazole. In contrast, only minor transcriptional changes were observed in the AP-naïve participants.

Conclusions

These findings suggest that prior antipsychotic exposure may have a priming effect on leukocyte gene expression, which results in a transcriptional response indicative of stress erythropoiesis and neutropoiesis when switching to a new antipsychotic drug. This response appears to be independent of psychosis symptom severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleAntipsychotic AgentsOlanzapineAmisulprideSchizophreniaGene ExpressionLeukocytesHumansMaleFemaleAdultMiddle AgedYoung Adult

Stichwörter der Autor:innen

antipsychoticserythroid cellsimmature neutrophil cellsschizophrenia spectrum and other psychotic disorderstranscriptomics

Substanzen

AripiprazoleAntipsychotic AgentsOlanzapineAmisulpride

Autor:innen und Institutionen

  • Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
  • Mohn Research Center for Psychotic Disorders (MRCP), Haukeland University Hospital, Bergen, Norway.
  • Interdisciplinary Pomeranian Centre for Digital Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland.
  • Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
  • TIPS - Network for Clinical Research in Psychosis, Stavanger University Hospital, Stavanger, Norway.

ORCID-Profile: Anja Torsvik

Förderung

  • Trond Mohn Research Foundation
  • Dr. Einar Martens Foundation
  • Western Norway Regional Health
  • Research Council of Norway

Zitieren

APA

Torsvik, A., Trentani, A., Stokowy, T. K., Skrede, S., Joa, I., Klæbo Reitan, S. M., Rettenbacher, M., Kroken, R. A., Johnsen, E., & Steen, V. M. (2026). Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders. International Journal of Neuropsychopharmacology, 29(6). https://doi.org/10.1093/ijnp/pyag019

Vancouver

Torsvik A, Trentani A, Stokowy TK, Skrede S, Joa I, Klæbo Reitan SM, et al. Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders. International Journal of Neuropsychopharmacology. 2026;29(6). doi:10.1093/ijnp/pyag019

BibTeX
@article{Torsvik2026,
  author = {Torsvik, Anja and Trentani, Andrea and Stokowy, Tomasz K and Skrede, Silje and Joa, Inge and Klæbo Reitan, Solveig M and Rettenbacher, Maria and Kroken, Rune A and Johnsen, Erik and Steen, Vidar M},
  title = {Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  volume = {29},
  number = {6},
  doi = {10.1093/ijnp/pyag019}
}
Kostenlos starten →